Insights from 2024 WCLC


 

WCLC 2024 Insights: LAURA Study - Osimertinib After Definitive CRT in Unresectable Stage III EGFRm NSCLC

94 views
September 18, 2024
Comments 0
Login to view comments. Click here to Login